TRIAL OF CELECOXIB IN LUNG CANCER CHEMOPREVENTION

$0P01FY2002CANIH

University Of Texas Md Anderson Can Ctr, Houston TX

Investigators

Linked publications & trials

Paper 24366692 Paper 23073998 Paper 22752582 Paper 22711340 Paper 21733820 Paper 20864511 Paper 20840865 Paper 20826545 Paper 20696139 Paper 20654584 Paper 20599780 Paper 20493977 Paper 20460401 Paper 20371723 Paper 20354190 Paper 20138025 Paper 20105430 Paper 20103722 Paper 20068065 Paper 20028769 Paper 19665429 Paper 19654295 Paper 19482682 Paper 19481061 Paper 19372569 Paper 19147543 Paper 19138944 Paper 19138934 Paper 18688862 Paper 18662800 Paper 18606397 Paper 18519703 Paper 18508572 Paper 18202022 Paper 18156302 Paper 18045141 Paper 18036510 Paper 17942934 Paper 17900314 Paper 17855663 Paper 17692826 Paper 17673602 Paper 17668425 Paper 17641059 Paper 17640567 Paper 17609425 Paper 17545551 Paper 17533369 Paper 17516865 Paper 17505005 Paper 17479394 Paper 17475222 Paper 17440100 Paper 17439942 Paper 17404114 Paper 17363495 Paper 17341611 Paper 17277159 Paper 17240359 Paper 17227227 Paper 17211725 Paper 17201169 Paper 17156272 Paper 17114179 Paper 17110449 Paper 17078054 Paper 17028156 Paper 17021000 Paper 17015749 Paper 17011176 Paper 16966432 Paper 16953224 Paper 16924232 Paper 16877726 Paper 16818501 Paper 16785236 Paper 16682954 Paper 16682409 Paper 16624823 Paper 16603641 Paper 16563357 Paper 16551868 Paper 16493072 Paper 16441231 Paper 16428513 Paper 16397209 Paper 16377638 Paper 16356126 Paper 16331857 Paper 16331273 Paper 16230421 Paper 16219905 Paper 16082211 Paper 16024620 Paper 16023083 Paper 16007145 Paper 15994961 Paper 15911972 Paper 15905586 Paper 15844661

Abstract

DESCRIPTION (provided by applicant): Current smokers have been the focus of recently completed, large-scale lung cancer chemoprevention trials, and the outcomes of these trials have been uniformly disappointing. There is an urgent need to understand the biologic effects of cigarette smoke on the bronchial epithelium in order to develop more effective lung cancer chemopreventive agents. Our findings indicate that bronchial metaplasia and dysplasia, which are forerunners of NSCLC, persist after smoking cessation, and we have detected clonal genetic abnormalities in histologically abnormal and normal areas of mucosa in former smokers. We have shown that the biology of the bronchial epithelium differs greatly in current and former smokers, and we hypothesize that these biologic differences are important determinants of response and resistance to lung cancer chemopreventive agents. To test this hypothesis we will perform a randomized, placebo-controlled biomarker-based clinical trial in current and former smokers, examining the effect of cyclooxygenase-2 (COX-2) inhibition on biomarkers of lung cancer risk and COX-2-dependent signaling pathways. Specific Aim 1 Hypothesis: Current and former smokers respond to the chemopreventive effects of COX-2 inhibitors, namely celecoxib. Aim: To examine the effect of celecoxib treatment on Ki-67 expression, a marker of cell proliferation, in the bronchial epithelium of current and former smokers. Specific Aim 2 Hypothesis: Current and former smokers tolerate treatment with COX-2 inhibitors. Aim: To examine the toxicity associated with celecoxib administration. Specific Aim 3 Hypothesis: Treatment with COX-2 inhibitors modulates COX-2- and lipoxygenase (LOX)-dependent signaling in the bronchial epithelium. Aim: To measure the effect of celecoxib treatment on arachidonic acid metabolites in the bronchial epithelium of current and former smokers.

View original record on NIH RePORTER →